InBio has applied its proven expertise in structural biology, protein expression and purification to manufacture recombinant SARS-CoV-2 proteins.
Spike and nucleocapsid proteins have been developed and will support diagnostic and therapeutic approaches, as well as research on the immune mechanisms involved in coronavirus infections.
Key characteristics of InBio SARS-CoV-2 proteins.
- Expression in mammalian and bacterial systems
- Manufactured & validated under an ISO 9001:2015 certified Quality Management System
- >95% purity as assessed by InBio® MS (mass spectrometry) & SDS-PAGE
- Validated by IgG antibody ELISA using serum samples from COVID-19 patients
- LoTox™ (low endotoxin, <0.03EU/µg protein) options available, ideal for T-cell and murine cellular studies
Silver-sained SDS-PAGE of SARS-CoV-2 Spike Protein Receptor Binding Domain (left) and the RNA-Binding Domain of the Nucleocapsid Protein (right)
Full-length Spike Protein binding to human IgG antibodies using sera samples from COVID-19 patients
